UAB RESEARCH FOUNDATION Patent applications |
Patent application number | Title | Published |
20160002315 | APOLIPOPROTEIN MIMETICS AND USES THEREOF - The disclosure provides dosing regimens and methods for treating atherosclerosis with an effective amount of Apo E mimetic to provide sustained therapeutic effects even after withdrawal of the treatment. The dosing regimens and methods involve a treatment cycle followed by a rest phase wherein a subject is administered an effective amount of an Apo E mimetic during the treatment cycle and no Apo E mimetic during the rest phase. The treatment cycle and the rest phase can vary. | 01-07-2016 |
20140274883 | NOVEL ANTIVIRAL COMPOUNDS FROM MARINE EXTRACTS - The subject invention pertains to novel biologically active extracts from marine algae and to biologically active fractions and components of these extracts. These extracts have been shown to possess antiviral properties. Pharmaceutical compositions comprising these extracts, or comprising biologically active fractions or components of these extracts, could be used in the treatment of viral diseases including influenza. | 09-18-2014 |
20140112951 | Vaccine and drug delivery by topical application of vectors and vector extracts - Disclosed and claimed is a method of non-invasive immunization in an animal and/or a method of inducing a systemic immune response or systemic therapeutic response to a gene product. The skin of the animal is contacted with a non-replicative vector chosen from the group of bacterium, virus, and fungus, wherein the vector comprises and expresses a nucleic acid molecule encoding the gene product, in an amount effective to induce the response. | 04-24-2014 |
20140099299 | Methods and Compositions for Cytomegalovirus IL-10 Protein - The present invention provides methods and compositions for treating and/or preventing a cytomegalovirus infection in a subject, comprising administering to the subject an effective amount of a cytomegalovirus IL-10 protein modified to have reduced functional activity while retaining immunogenicity. The present invention further provides nucleic acid molecules encoding a cytomegalovirus IL-10 protein or fragment thereof of this invention as well as vectors comprising such nucleic acids. Also provided herein are neutralizing antibodies that specifically bind cmvIL-10. | 04-10-2014 |
20140080125 | Polymorphisms in the FCGR2B Promoter and Uses Thereof - The invention relates to the FCGR2B gene and its promoter. In particular, the invention relates to FCGR2B promoters with specific nucleotides at polymorphic sites. Characterization of the nucleotides at polymorphic sites is useful for characterizing the gene and the protein and is useful for determining predisposition or susceptibility to certain diseases and infections in a subject or a population of subjects. Such characterization of the gene or protein is also useful for determining immunoresponsiveness or responsiveness to therapeutic agents in a subject or population of subjects. Thus, disclosed herein are a variety of related nucleic acids, methods and tools. | 03-20-2014 |
20140079734 | Methods and Compositions for Alphavirus Replicons - The present invention provides alphavirus replicons and methods of their use in producing heterologous protein. | 03-20-2014 |
20140065178 | Methods and Compositions for Pseudoinfectious Alphaviruses - The present invention provides pseudoinfectious alphavirus particles and methods of making them and using them to produce an immune response to an alphavirus in a subject. | 03-06-2014 |
20130260339 | HIGH TORQUE DENTAL IMPLANT SYSTEM - A dental implant system for securing a dental prosthesis within a prepared site of a jawbone in a subject having an implant configured for insertion within the prepared site of the jawbone and an abutment configured for secure attachment to the implant. The implant can have a shoulder portion having a plurality of circumferential rings and a body portion that can be threaded. The implant can have an internal cavity that is configured or otherwise adapted to receive at least a portion of the abutment. | 10-03-2013 |
20130216576 | PNEUMOCOCCAL SEROTYPE 6D - Disclosed is a new and emerging serotype of | 08-22-2013 |
20130097644 | Generation and Consumption of Discrete Segments of Digital Media - Provided are systems and methods of accessing a portion of a media file on a remote server. The method can comprise receiving a first uniform resource identifier associated with the media file; generating a first boundary point and a second boundary point associated with the portion of the media file, each of the first and second boundary points corresponding to a point in time between the beginning and ending points in time of the media file; generating a second uniform resource identifier configured to locate the portion of the media file between the first and the second boundary points; requesting from the remote server at least a part of the media file associated with the first uniform resource identifier; receiving at least the part of the media file from the remote server; and rendering the media file starting at the first boundary point and ending at the second boundary point. | 04-18-2013 |
20110002890 | Treatment of tumors with genetically engineered herpes virus - Disclosed are methods for treating cancer by administering an effective amount of a modified Herpes simplex virus. | 01-06-2011 |
20090192215 | Cytotoxin Compounds and Methods of Isolation - The present invention concerns groups of compounds derived from tunicates of the | 07-30-2009 |
20090162390 | Molecular Scaffolds for HIV-1 Immunogens - Methods and compositions are provided which employ chimeric polypeptides having at least one heterologous epitope for a human immunodeficiency virus type 1 (HIV-1) neutralizing antibody. These chimeric polypeptides behave as molecular scaffolds which are capable of presenting the various heterologous HIV-1 epitopes. The invention demonstrates that a heterologous epitope recognized by the HIV-1 neutralizing antibody can be more fully exposed to neutralizing antibodies when presented within the backbone of the chimeric polypeptide than when the epitope is presented within the context of an HIV-1 backbone. Polynucleotides encoding these chimeric polypeptides are also provided. Immunogenic compositions are provided which comprise a chimeric polypeptide having at least one heterologous epitope that interacts with an HIV-1 neutralizing antibody. Immuno genie compositions comprising chimeric polynucleotides encoding the chimeric polypeptides of the invention are also provided. Vaccines comprising such immunogenic compositions are also provided. Further provided are methods which employ the immunogenic compositions of the invention. Such methods include, for example, methods for eliciting an immune response in a subject, methods for generating antibodies specific for the chimeric polypeptide or the chimeric polypeptide, and methods for inhibiting or preventing infection by HIV-1 in a subject. | 06-25-2009 |
20090153802 | Method and apparatus for the detection of impaired dark adaptation - The present method describes a new method for the measurement of dark adaptation. The dark adaptation status of subjects may ten be used to identify those subjects who are at risk of developing and/or who are currently suffering from a variety of disease states having their clinical manifestations in impaired dark adaptation. The disease states include, but are not limited to, age related macular degeneration, vitamin A deficiency, Sorsby's Fundus Dystrophy, late autosomal dominant retinal degeneration, retinal impairment related to diabetes and diabetic retinopathy. An apparatus for administering the test method described is also provided. | 06-18-2009 |
20080248465 | Polymorphisms in the Fcgr2b Promoter and Uses Thereof - The invention relates to the FCGR2B gene and its promoter. In particular, the invention relates to FCGR2B promoters with specific nucleotides at polymorphic sites. Characterization of the nucleotides at polymorphic sites is useful for characterizing the gene and the protein and is useful for determining predisposition or susceptibility to certain diseases and infections in a subject or a population of subjects. Such characterization of the gene or protein is also useful for determining immunoresponsiveness or responsiveness to therapeutic agents in a subject or population of subjects. Thus, disclosed herein are a variety of related nucleic acids, methods and tools. | 10-09-2008 |